Hence, there is an urgent need to develop a new 18F-labeled CXCR4-targeted radiotracer endowing with high imaging contrast and CXCR4-specific accumulation both in solid tumors and hematologic neoplasms. This evidence concerns the gene CXCR4 and hematopoietic and lymphoid system neoplasm.